US43157M1027 - Common Stock
After hours stock analysis on 2024-12-05: top gainers and losers in today's session.
$189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024 The company is exploring the potential for continued...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ: HLVX). Such investors are...
HLVX stock results show that HilleVax missed analyst estimates for earnings per share the second quarter of 2024.
$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ: HLVX). Such investors are...
BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ: HLVX). Such investors are...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ: HLVX). Such investors are...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ: HLVX). Such investors are...
Grifols stock is up on Monday as the founding family of the company has presented a preliminary takeover offer for GRFS shares.
HilleVax stock is down on Monday after HLVX investors learned of a failed Phase 2b clinical trial of its norovirus vaccine for infants.
The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development of HIL-214 in...
HLVX stock results show that HilleVax missed analyst estimates for earnings per share the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips HilleVax (NASDAQ:HLVX) just reported results for the first quarter of 2024.Hill...
HLVX stock results show that HilleVax beat analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips HilleVax (NASDAQ:HLVX) just reported results for the fourth quarter of 2023.Hil...
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 Enrollment for NEST-IN1 study completed in Q2 2023 ...
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and...